📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-19 16:54
351 analysed today
FollowTelegram
351
Today
149,752
All-time analysed
42,937
Positive
6,664
Negative
91,466
Neutral
8,617
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
23 announcements match the current filters (relevance ≥ 5).
Anuh Pharma Q1 FY27 PAT Up 37.6% YoY to ₹11.42 Cr, EBITDA Jumps 41.6% to ₹19.36 Cr
Anuh Pharma released its Q1 FY27 investor presentation, reporting a 3.93% YoY growth in operating revenue to ₹193.81 crore. Operating profitability saw significant expansion, with EBITDA rising 41.56% YoY to ₹19.36 crore and EBITDA margins improving from 7.34% to 9.99%. Profit After Tax (PAT) grew 37.63% YoY to ₹11.42 crore, driven by a richer product mix and higher throughput from regulated markets. Production volume increased 19.46% YoY to 491 MT, with ROCE improving by 326 bps to 19.18%.
Confidence: HIGH
What changedAnuh Pharma published its Q1 FY27 investor presentation outlining financial metrics, product/geographic mix, and pipeline development.
Why it mattersDemonstrates operating leverage and margin recovery from a higher-margin product mix and USFDA/EU GMP regulated market ramp-ups across its 2,400 MTPA facility.
Q1 FY27 Revenue: ₹193.81 CrQ1 FY27 EBITDA: ₹19.36 CrQ1 FY27 PAT: ₹11.42 CrTotal Installed Capacity: 2,400 MTPAQ1 FY27 Production: 491 MT
📅 Short termThe strong YoY operational margin expansion to 9.99% is likely to be viewed constructively by market participants.
📈 Long termLong-term growth remains tied to capacity utilisation of the 2,400 MTPA facility, penetration in regulated markets, and successful commercialisation of high-value new APIs.
⚠ Risk flags
- Raw material price volatility affecting commodity API realisations
- Customer concentration with top 5 customers accounting for 34% of sales in Q1 FY27
Key Highlights
Operating revenue rose 3.93% YoY to ₹193.81 crore from ₹186.48 crore in Q1 FY26
EBITDA increased 41.56% YoY to ₹19.36 crore with margin expansion to 9.99% (vs 7.34% in Q1 FY26)
PAT surged 37.63% YoY to ₹11.42 crore, while basic EPS stood at ₹1.14 vs ₹0.83 in Q1 FY26
Production expanded 19.46% YoY to 491 MT against total installed capacity of 2,400 MTPA
Annual growth target guided at 15-20% per annum supported by pipeline molecules like Vonoprazan Fumarate and Pretomanid
👀 What to Watch
Track the commercialisation timeline of new pipeline APIs (Pretomanid, Vonoprazan Fumarate) and regulatory clearance ramp-up across regulated export markets in subsequent quarterly disclosures.
37.6% YoY PAT Growth in Q1 FY27; EBITDA Margins Expand to 9.99%
Anuh Pharma reported a steady Q1 FY27 with revenue from operations growing 3.9% YoY to ₹193.81 Cr. The company saw a significant expansion in profitability, with Net Profit (PAT) rising 37.6% YoY to ₹11.42 Cr, driven by improved operational efficiency as EBITDA margins rose from 7.34% to 9.99%. While YoY performance is strong, revenue saw a marginal 4.1% sequential (QoQ) decline from ₹202.12 Cr. The company maintains a robust balance sheet with zero debt and a net worth of ₹352 Cr.
Confidence: HIGH
What changedAnuh Pharma released its Q1 FY27 financial results, showing a significant jump in profitability and margin expansion despite modest revenue growth.
Why it mattersThe margin expansion suggests better cost management or a shift toward higher-margin products, which is critical for a medium-sized player in the competitive API industry.
Revenue (Q1 FY27): ₹193.81 CrNet Profit (Q1 FY27): ₹11.42 CrEBITDA Margin: 9.99%YoY PAT Growth: 37.6%Debt-to-Equity Ratio: 0.00Quarterly EPS: ₹1.14
📅 Short termThe stock may see positive sentiment in the short term due to the strong bottom-line growth and margin improvement exceeding revenue growth.
📈 Long termLong-term value depends on the successful diversification beyond core macrolides and increasing the share of revenue from regulated markets like Western Europe and Mexico.
⚠ Risk flags
- Raw material price volatility
- Intense price-based competition in commoditized APIs
- Regulatory compliance risks for exports to regulated markets
Key Highlights
Revenue from operations increased to ₹193.81 Cr in Q1 FY27 from ₹186.48 Cr in Q1 FY26.
Net Profit after tax grew 37.6% YoY to ₹11.42 Cr compared to ₹8.30 Cr in the previous year's quarter.
EBITDA margins expanded by 265 basis points YoY to reach 9.99%.
Finance costs remained negligible at ₹0.35 Lakhs, reflecting a debt-free status.
Earnings Per Share (EPS) improved to ₹1.14 from ₹0.83 in the corresponding quarter last year.
👀 What to Watch
Watch for the continued ramp-up of the 1,500 MTPA capacity and the company's ability to maintain margins amidst raw material price volatility in the commoditized API segment.
37.6% PAT Growth in Q1 FY27; EBITDA Margins Expand to 9.99%
Anuh Pharma reported a strong 37.6% YoY increase in net profit to ₹11.42 Cr for the quarter ended June 30, 2026, despite a modest 3.9% growth in revenue to ₹193.81 Cr. The performance was driven by significant margin expansion, with EBITDA margins rising to 9.99% from 7.34% in the same period last year. Additionally, three promoter group members holding a combined 0.83% stake withdrew their requests to be reclassified as public shareholders, choosing to remain in the promoter group. The company also adopted a revised policy on Related Party Transactions.
Confidence: HIGH
What changedAnuh Pharma released its Q1 FY27 results showing significant profit growth and margin improvement, alongside a decision by certain promoter group members to maintain their promoter status.
Why it mattersThe margin expansion is critical for a medium-sized API player in a commoditized market, suggesting better operational efficiency or a favorable product mix despite rising raw material costs.
Revenue (Q1 FY27): ₹193.81 CrNet Profit (Q1 FY27): ₹11.42 CrEBITDA Margin: 9.99%YoY PAT Growth: 37.6%Promoter Stake Withdrawn: 0.83%
📅 Short termThe stock may see positive sentiment in the short term due to the sharp improvement in profitability and margins compared to the previous year.
📈 Long termLong-term value depends on the company's ability to diversify beyond core macrolides and successfully penetrate regulated markets like Western Europe and Mexico using its expanded capacity.
⚠ Risk flags
- Raw material price volatility (material costs rose 29% YoY)
- Limited pricing power in commoditized API markets
- High dependence on regulated market certifications (55% of revenue)
Key Highlights
Net Profit (PAT) grew 37.6% YoY to ₹11.42 Cr from ₹8.30 Cr in Q1 FY26.
EBITDA margins expanded by 265 basis points to 9.99% compared to 7.34% YoY.
Revenue from operations increased 3.9% YoY to ₹193.81 Cr from ₹186.48 Cr.
Promoter group members holding 8,31,748 shares (0.83% stake) withdrew their reclassification applications.
Cost of materials consumed rose to ₹159.96 Cr from ₹123.91 Cr, reflecting raw material price shifts.
👀 What to Watch
Investors should monitor if the company can sustain these improved EBITDA margins above 9% in the coming quarters and track the volume ramp-up from the recently expanded 1,500 MTPA capacity.
Anuh Pharma FY26 Revenue Up 15.7% to ₹776 Cr; USFDA Inspection Passed with Zero Observations
Anuh Pharma Limited reported a 15.66% YoY growth in annual revenue to ₹776 Cr for FY26, supported by a 25% increase in production volumes. Despite the top-line growth, the company faced margin pressure, with PAT declining 13.32% YoY to ₹41.05 Cr and EBITDA margins contracting to 8.56% from 10.64%. A significant positive is the successful completion of USFDA and EU GMP inspections in May 2026 with zero Form 483 observations, paving the way for further expansion into regulated markets.
Key Highlights
Annual revenue grew 15.66% to ₹776 Cr, while Q4 FY26 revenue remained flat at ₹201 Cr.
Successfully cleared USFDA and EU GMP inspections in May 2026 with zero Form 483 observations.
Total production volume surged 24.99% YoY to 1,733 MT, reflecting high plant utilization.
Net Profit (PAT) for FY26 fell to ₹41.05 Cr from ₹47.35 Cr in the previous year due to margin compression.
Manufacturing capacity was expanded to 2,400 MTPA in 2025, up from 2,200 MTPA.
👀 What to Watch
Investors should weigh the strong regulatory compliance and volume growth against the declining profit margins. While the USFDA clearance is a long-term positive for market access, the immediate focus should be on the company's ability to recover profitability in a high-volume, low-margin environment.
Anuh Pharma FY26 Revenue Grows 16.6% to ₹771.6 Cr, Proposes ₹1.50 Dividend
Anuh Pharma reported a 16.6% YoY increase in FY26 revenue to ₹77,165.74 Lakhs, though annual PAT fell 13.3% to ₹4,104.61 Lakhs. For Q4 FY26, revenue was ₹20,211.72 Lakhs with a PAT of ₹1,168.14 Lakhs, showing a slight decline in profitability compared to the previous year. The company recommended a final dividend of ₹1.50 per share and is processing a promoter re-classification request for 0.95% of equity. EBITDA margins for the year compressed to 8.56% from 10.64% in FY25.
Key Highlights
FY26 Revenue increased to ₹77,165.74 Lakhs from ₹66,151.49 Lakhs in FY25.
FY26 PAT declined to ₹4,104.61 Lakhs vs ₹4,735.19 Lakhs, impacted by higher material costs.
Board recommended a final dividend of ₹1.50 per share (30% of face value).
EBITDA margin for FY26 stood at 8.56% compared to 10.64% in the previous fiscal.
Nine promoter group entities holding 0.95% stake sought re-classification to the public category.
👀 What to Watch
While revenue growth is healthy, the margin contraction and PAT decline are concerns; investors should monitor management commentary on cost pressures. The ₹1.50 dividend offers some yield support for long-term holders.
Anuh Pharma FY26 Revenue Grows 16.6% to ₹771.6 Cr; PAT Declines 13.3%; ₹1.50 Dividend Declared
Anuh Pharma reported a 16.6% year-on-year increase in annual revenue to ₹771.66 crore for FY26. However, Profit After Tax (PAT) declined by 13.3% to ₹41.05 crore, largely due to margin compression as EBITDA margins fell from 10.64% to 8.56%. The Board has recommended a final dividend of ₹1.50 per share (30% on face value), and the company is processing a re-classification of 0.95% of promoter group holdings to the public category.
Key Highlights
Annual Revenue from Operations increased to ₹77,165.74 lakhs from ₹66,151.49 lakhs in FY25
Net Profit for the full year decreased to ₹4,104.61 lakhs compared to ₹4,735.19 lakhs in the previous year
EBITDA margin contracted to 8.56% in FY26 from 10.64% in FY25 due to higher material costs
Recommended a final dividend of ₹1.50 per equity share of face value ₹5 each
Promoter group re-classification involves 9,49,988 shares representing 0.95% of total shareholding
👀 What to Watch
Investors should monitor the company's ability to pass on rising raw material costs, as margins have significantly contracted despite strong top-line growth. The dividend provides a steady yield, but the decline in bottom-line profitability warrants a cautious approach.
Anuh Pharma FY26 Revenue Grows 16.6% to ₹771.6 Cr; Recommends ₹1.50 Final Dividend
Anuh Pharma reported a 16.6% year-on-year growth in annual revenue for FY26, reaching ₹771.66 crore. However, annual net profit declined by 13.3% to ₹41.05 crore as EBITDA margins contracted from 10.64% to 8.56%. For Q4 FY26, revenue was ₹202.12 crore with a net profit of ₹11.68 crore, showing a slight year-on-year decline in earnings. The company has recommended a final dividend of ₹1.50 per share, representing a 30% payout on the face value of ₹5.
Key Highlights
FY26 Revenue from operations rose 16.6% YoY to ₹77,165.74 Lakhs.
Annual Net Profit fell 13.3% to ₹4,104.61 Lakhs due to margin pressure.
EBITDA margin for the full year compressed to 8.56% from 10.64% in FY25.
Board recommended a final dividend of ₹1.50 per share (30% on FV of ₹5).
Inventories nearly doubled to ₹14,775.50 Lakhs compared to ₹7,448.09 Lakhs in the previous year.
👀 What to Watch
While top-line growth is healthy, the contraction in margins and rising inventory levels are areas of concern. Investors should monitor management's ability to pass on cost increases and manage working capital before increasing exposure.
Anuh Pharma FY26 Revenue Grows 16.6% to ₹771.6 Cr; Recommends ₹1.50 Dividend
Anuh Pharma reported a 16.6% year-on-year growth in annual revenue for FY26, reaching ₹77,165.74 lakhs. However, annual net profit declined by 13.3% to ₹4,104.61 lakhs as EBITDA margins contracted from 10.64% to 8.56%. For the fourth quarter, revenue was stagnant at ₹20,211.72 lakhs compared to ₹19,813.95 lakhs in the previous year's quarter. The company has recommended a final dividend of ₹1.50 per share, representing 30% of the face value.
Key Highlights
Annual Revenue from operations increased 16.6% YoY to ₹77,165.74 lakhs.
Full-year Net Profit fell to ₹4,104.61 lakhs from ₹4,735.19 lakhs in FY25.
EBITDA margin for FY26 compressed to 8.56% compared to 10.64% in the previous year.
Recommended a final dividend of ₹1.50 per equity share (30% of face value).
Inventory levels nearly doubled YoY to ₹14,775.50 lakhs, impacting cash flow from operations.
👀 What to Watch
Investors should exercise caution as the company is facing margin pressure despite top-line growth. Monitor the high inventory levels and raw material cost trends in the bulk drug segment before making new positions.
Anuh Pharma FY26 Revenue Grows 16.6% to ₹771.6 Cr; Recommends ₹1.50 Final Dividend
Anuh Pharma reported a 16.6% YoY growth in annual revenue from operations to ₹77,165.74 Lakhs for FY26. However, annual net profit declined by 13.3% to ₹4,104.61 Lakhs, primarily due to higher material costs and a mark-to-market loss on investments. The company recommended a final dividend of ₹1.50 per share following a 1:1 bonus issue earlier in the year. Inventory levels nearly doubled to ₹14,775.50 Lakhs, which significantly impacted operating cash flow for the year.
Key Highlights
Annual Revenue from operations increased to ₹77,165.74 Lakhs in FY26 from ₹66,151.49 Lakhs in FY25.
Net Profit for FY26 stood at ₹4,104.61 Lakhs, down from ₹4,735.19 Lakhs in the previous year.
Recommended a final dividend of ₹1.50 per equity share (30% on face value of ₹5).
EBITDA margin for FY26 contracted to 8.56% compared to 10.64% in FY25.
Inventory levels surged to ₹14,775.50 Lakhs as of March 31, 2026, compared to ₹7,448.09 Lakhs in the previous year.
👀 What to Watch
Investors should monitor the company's ability to manage rising material costs and inventory levels, which have pressured margins and cash flows. While revenue growth is healthy, the contraction in profitability and high inventory buildup warrant a cautious approach.
Anuh Pharma FY26 Revenue grows 16.6% to ₹771.6 Cr; PAT declines 13.3% to ₹41.0 Cr
Anuh Pharma reported a 16.6% year-on-year growth in annual revenue to ₹771.66 crore for FY26, though Q4 revenue remained relatively flat at ₹202.12 crore. Profitability faced pressure as annual PAT declined by 13.3% to ₹41.05 crore, primarily due to higher material costs and a compression in EBITDA margins from 10.64% to 8.56%. The Board has recommended a final dividend of ₹1.50 per share (30% of face value). Despite the profit dip, the company maintains a strong balance sheet with zero long-term debt, though inventory levels nearly doubled during the year.
Key Highlights
Annual Revenue from operations increased to ₹77,165.74 Lakhs in FY26 from ₹66,151.49 Lakhs in FY25.
Net Profit After Tax (PAT) for the full year fell to ₹4,104.61 Lakhs compared to ₹4,735.19 Lakhs in the previous year.
EBITDA margins for FY26 contracted significantly to 8.56% from 10.64% in FY25.
Recommended a final dividend of ₹1.50 per equity share of face value ₹5 each.
Inventory levels surged to ₹14,775.50 Lakhs as of March 31, 2026, compared to ₹7,448.09 Lakhs in the previous year.
👀 What to Watch
Investors should monitor the company's ability to pass on raw material costs to recover margins and watch the utilization of the high inventory levels which impacted operating cash flows.
Anuh Pharma FY26 Revenue Up 16.6% to ₹771.6 Cr; Recommends ₹1.50 Final Dividend
Anuh Pharma reported a 16.6% YoY growth in annual revenue to ₹771.66 crore for FY26, although net profit for the year declined by 13.3% to ₹41.05 crore. The company faced significant margin pressure, with EBITDA margins contracting to 8.56% from 10.64% in the previous fiscal year. Despite the profit dip, the Board has recommended a final dividend of ₹1.50 per share. A notable concern is the near doubling of inventory levels to ₹147.76 crore, which led to negative cash flow from operations of ₹3.01 crore.
Key Highlights
Annual Revenue from operations grew 16.6% YoY to ₹77,165.74 Lakhs.
Full-year Net Profit decreased to ₹4,104.61 Lakhs from ₹4,735.19 Lakhs in FY25.
EBITDA margins contracted significantly to 8.56% compared to 10.64% in the previous year.
Board recommended a final dividend of ₹1.50 per equity share (30% on face value of ₹5).
Inventory levels surged to ₹14,775.50 Lakhs from ₹7,448.09 Lakhs YoY, impacting liquidity.
👀 What to Watch
Investors should weigh the healthy top-line growth against the sharp contraction in margins and rising inventory levels. The stock may see support from the dividend announcement, but clarity is needed on the operational efficiency and raw material cost management.
Anuh Pharma FY26 Revenue Grows 16.6% to ₹771.6 Cr; Recommends ₹1.50 Final Dividend
Anuh Pharma reported a 16.6% year-on-year growth in annual revenue for FY26, reaching ₹771.65 crore. However, annual net profit declined by 13.3% to ₹41.05 crore compared to ₹47.35 crore in the previous year, primarily due to compressed EBITDA margins which fell from 10.64% to 8.56%. For the fourth quarter, revenue remained relatively flat at ₹202.12 crore, while profit after tax saw a slight dip to ₹11.68 crore. The board has recommended a final dividend of ₹1.50 per share (30% on face value of ₹5).
Key Highlights
Annual Revenue from operations grew 16.6% YoY to ₹77,165.74 Lakhs in FY26.
Full-year Net Profit decreased to ₹4,104.61 Lakhs from ₹4,735.19 Lakhs in FY25.
EBITDA margin for FY26 contracted to 8.56% compared to 10.64% in the previous fiscal year.
Recommended a final dividend of ₹1.50 per equity share (30%) for the financial year.
Inventory levels significantly increased to ₹14,775.50 Lakhs from ₹7,448.09 Lakhs YoY.
👀 What to Watch
Investors should monitor the margin recovery in the bulk drugs segment as rising material costs impacted the bottom line despite higher sales. The dividend provides some yield, but the decline in annual profitability warrants a cautious outlook until margins stabilize.
Anuh Pharma FY26 Revenue Grows 16.6% to ₹771.6 Cr; Recommends ₹1.50 Dividend
Anuh Pharma Limited reported a 16.6% year-on-year growth in annual revenue for FY26, reaching ₹77,165.74 Lakhs. However, annual net profit declined by 13.3% to ₹4,104.61 Lakhs, as EBITDA margins compressed from 10.64% to 8.56%. The company has recommended a final dividend of ₹1.50 per share (30% of face value) and appointed Mr. P. N. Rao as General Manager - Quality to strengthen its operational leadership.
Key Highlights
Annual Revenue from operations increased to ₹77,165.74 Lakhs in FY26 from ₹66,151.49 Lakhs in FY25.
Net Profit for the full year FY26 stood at ₹4,104.61 Lakhs, down from ₹4,735.19 Lakhs in the previous year.
EBITDA margins saw a contraction, falling to 8.56% in FY26 compared to 10.64% in FY25.
The Board recommended a final dividend of ₹1.50 per equity share of ₹5 face value.
Inventory levels nearly doubled to ₹14,775.50 Lakhs as of March 31, 2026, compared to ₹7,448.09 Lakhs in the previous year.
👀 What to Watch
Investors should monitor the company's ability to recover margins and manage the significant increase in inventory, which has impacted operating cash flows. The dividend offers some yield, but the decline in bottom-line profitability despite top-line growth suggests rising input or operational costs.
Anuh Pharma FY26 Revenue Up 16.6% to ₹771.6 Cr; Net Profit Dips 13.3% to ₹41 Cr
Anuh Pharma Limited reported a 16.6% increase in annual revenue for FY26, reaching ₹771.65 crore compared to ₹661.51 crore in FY25. However, annual net profit declined by 13.3% to ₹41.05 crore, primarily due to EBITDA margin compression from 10.64% to 8.56%. For the fourth quarter, revenue was stable at ₹202.12 crore, but profit dipped slightly to ₹11.68 crore. The company has recommended a final dividend of ₹1.50 per share.
Key Highlights
Annual Revenue from operations grew 16.6% YoY to ₹77,165.74 Lakhs.
Full-year Net Profit after Tax (PAT) decreased to ₹4,104.61 Lakhs from ₹4,735.19 Lakhs in FY25.
EBITDA margin for FY26 contracted to 8.56% compared to 10.64% in the previous year.
Board recommended a final dividend of ₹1.50 per equity share (30% of face value).
Inventory levels saw a significant jump to ₹14,775.50 Lakhs from ₹7,448.09 Lakhs YoY.
👀 What to Watch
Investors should monitor the margin contraction and the sharp increase in inventory levels which may impact future cash flows. While revenue growth is positive, the decline in profitability suggests rising operational costs that need to be addressed.
Anuh Pharma FY26 Revenue Up 16.6% to ₹771.66 Cr; Recommends ₹1.50 Dividend
Anuh Pharma reported a 16.6% year-on-year growth in annual revenue for FY26, reaching ₹771.66 crore. However, net profit for the full year declined by 13.3% to ₹41.05 crore compared to ₹47.35 crore in FY25, impacted by higher material costs and mark-to-market losses on investments. The board has recommended a final dividend of ₹1.50 per share (30% of face value) and fixed August 5, 2026, as the record date. The company also noted a 1:1 bonus issue completed in July 2025, which adjusted the earnings per share figures.
Key Highlights
Annual Revenue from operations grew 16.6% YoY to ₹771.66 crore in FY26.
Net Profit for FY26 decreased to ₹41.05 crore from ₹47.35 crore in the previous year.
Board recommended a final dividend of ₹1.50 per equity share of face value ₹5.
Q4 FY26 EBITDA margin stood at 9.22%, down from 10.13% in Q4 FY25.
Record date for dividend eligibility and AGM voting is fixed as August 5, 2026.
👀 What to Watch
Investors should monitor the company's ability to manage rising raw material costs, which have pressured margins despite strong revenue growth. The steady dividend payout remains a positive for income-seeking investors, but the profit decline warrants a cautious outlook on valuation.
Anuh Pharma Reports FY26 Revenue of ₹771.6 Cr, Recommends ₹1.50 Final Dividend
Anuh Pharma reported a 16.6% year-on-year growth in revenue for FY26, reaching ₹771.65 crore. However, net profit for the full year declined by 13.3% to ₹41.05 crore, primarily due to compressed EBITDA margins which fell from 10.64% to 8.56%. The board has recommended a final dividend of ₹1.50 per share (30% payout on face value), with the record date set for August 5, 2026. The company also noted that 0.95% of promoter group holdings are seeking reclassification to the public category.
Key Highlights
Revenue from operations grew 16.6% YoY to ₹771.65 crore in FY26.
Net Profit (PAT) decreased by 13.3% YoY to ₹41.05 crore for the full year.
Recommended a final dividend of ₹1.50 per equity share of face value ₹5.
EBITDA margin contracted to 8.56% in FY26 from 10.64% in the previous year.
Record date for dividend eligibility and AGM voting is fixed for August 5, 2026.
👀 What to Watch
Investors should monitor the margin compression despite healthy revenue growth, as rising material costs appear to be impacting the bottom line. The dividend provides a steady yield, but long-term performance will depend on the company's ability to restore operational efficiency.
Anuh Pharma FY26 Revenue Up 16.6% to ₹771.6 Cr, PAT Down 13.3%; ₹1.50 Dividend Declared
Anuh Pharma reported a healthy 16.6% YoY growth in annual revenue to ₹771.66 crore for FY26. However, net profit for the year declined by 13.3% to ₹41.05 crore, primarily driven by a contraction in EBITDA margins from 10.64% to 8.56%. The Board has recommended a final dividend of ₹1.50 per share (30% of face value). Additionally, the company is seeking to re-classify 0.95% of its shareholding from the Promoter Group to the Public category.
Key Highlights
Annual Revenue from operations increased to ₹77,165.74 Lakhs in FY26 from ₹66,151.49 Lakhs in FY25.
Net Profit for the full year declined to ₹4,104.61 Lakhs compared to ₹4,735.19 Lakhs in the previous fiscal.
Recommended a final dividend of ₹1.50 per equity share (30% payout on face value of ₹5).
EBITDA margin contracted to 8.56% for FY26, down from 10.64% in FY25 due to higher material costs.
Approved re-classification of 9,49,988 shares (0.95% stake) held by 9 individuals from Promoter to Public category.
👀 What to Watch
While top-line growth is encouraging, investors should exercise caution regarding the declining profit margins and rising cost of materials. Monitor the company's ability to pass on costs in the upcoming quarters before increasing exposure.
Anuh Pharma Receives WHO Prequalification for Amodiaquine Hydrochloride API
Anuh Pharma Limited has successfully secured World Health Organization (WHO) Prequalification for its Amodiaquine Hydrochloride USP, a key anti-malarial Active Pharmaceutical Ingredient (API). This approval allows the company to supply the API to international markets, specifically targeting WHO-procured and donor-funded programs. Amodiaquine is a critical component in combination therapies for treating malaria, and this certification enhances the company's global competitiveness. The milestone is expected to strengthen Anuh Pharma's position as a preferred supplier for large-scale global health initiatives.
Key Highlights
Received WHO Prequalification (WHO PQ) for Amodiaquine Hydrochloride USP API.
Enables access to international donor-funded and WHO-procured procurement programs.
Product is an essential medicine used in combination therapies for Plasmodium falciparum malaria.
Strengthens the company's standing as a preferred global supplier in the anti-malarial segment.
👀 What to Watch
Investors should view this as a significant regulatory win that opens high-volume export opportunities; monitor for upcoming supply contracts and volume growth in the API segment.
Anuh Pharma Facilities Found Compliant in EDQM Audit
Anuh Pharma Limited has successfully completed an audit by the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its manufacturing facilities in Tarapur, Maharashtra. The audit covered units E-17/3, E-17/4, and E-18, all of which were found to be compliant with global quality standards. This successful inspection is a significant milestone as it ensures the company's continued access to European markets for its pharmaceutical products. The compliance reaffirms the company's commitment to high regulatory standards, potentially boosting investor confidence in its export capabilities.
Key Highlights
EDQM audit successfully completed for three manufacturing units in Tarapur, Maharashtra.
Facilities E-17/3, E-17/4, and E-18 were found fully compliant with European quality standards.
The successful inspection reaffirms the company's adherence to global regulatory benchmarks.
Ensures uninterrupted access to the European market for the company's pharmaceutical products.
👀 What to Watch
This regulatory clearance reduces operational risk and strengthens the company's export profile. Investors can maintain their positions as this secures a key revenue stream from the European region.
Anuh Pharma Q3 FY26: Revenue Grows 23% YoY; Zero USFDA Observations Reported
Anuh Pharma reported a robust Q3 FY26 with revenue at ₹201 Cr and a significant sequential recovery in EBITDA margins to 10.60%. A major highlight is the successful USFDA inspection in February 2026 with zero Form 483 observations, strengthening its position in regulated markets. While 9M FY26 PAT is down 15.85% YoY to ₹29.36 Cr, the quarterly performance shows strong momentum with PAT rising 76.7% QoQ. The company has also expanded its production capacity to 2,400 MTPA to meet growing demand.
Key Highlights
9M FY26 Revenue increased 22.9% YoY to ₹578.02 Cr compared to ₹471.43 Cr in 9M FY25.
Successful USFDA inspection in Feb 2026 with zero Form 483 observations reinforces regulatory excellence.
Q3 FY26 PAT surged 76.7% QoQ to ₹13.45 Cr from ₹7.61 Cr in the preceding quarter.
Total manufacturing capacity enhanced to 2,400 MTPA in 2025 from 2,200 MTPA.
EBITDA for Q3 FY26 stood at ₹20.91 Cr, representing 10.60% of sales compared to 6.92% in Q2 FY26.
👀 What to Watch
The zero USFDA observations and strong sequential margin recovery are significant positive triggers for the stock. Investors should monitor the company's ability to sustain these margins as it utilizes its newly expanded 2,400 MTPA capacity.
